CL2011000742A1 - Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion. - Google Patents

Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion.

Info

Publication number
CL2011000742A1
CL2011000742A1 CL2011000742A CL2011000742A CL2011000742A1 CL 2011000742 A1 CL2011000742 A1 CL 2011000742A1 CL 2011000742 A CL2011000742 A CL 2011000742A CL 2011000742 A CL2011000742 A CL 2011000742A CL 2011000742 A1 CL2011000742 A1 CL 2011000742A1
Authority
CL
Chile
Prior art keywords
bhv
modifications
encodes
suppress
protein
Prior art date
Application number
CL2011000742A
Other languages
English (en)
Inventor
Seetharaman Gopinath Raju
Richard Harland
Ii Lee David Albee
Mayur Navnitbhai Patel
Benedikt B Kaufer
Nikolaus Osterrieder
Original Assignee
Novartis Tiergesundheit Ag
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Tiergesundheit Ag, Univ Cornell filed Critical Novartis Tiergesundheit Ag
Publication of CL2011000742A1 publication Critical patent/CL2011000742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Virus herpes bovino 1 (bhv-1) porque posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteína que puede suprimir el sistema inmune de un huésped infectado; composición que comprende dicho bhv-1 ; método para despertar una respuesta inmunológica en un huésped; uso de bhv-1 vivo que posee modificaciones de ul49.5 y ul41 o us4.
CL2011000742A 2008-10-03 2011-04-01 Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion. CL2011000742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19510208P 2008-10-03 2008-10-03

Publications (1)

Publication Number Publication Date
CL2011000742A1 true CL2011000742A1 (es) 2011-10-14

Family

ID=41354075

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000742A CL2011000742A1 (es) 2008-10-03 2011-04-01 Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion.

Country Status (12)

Country Link
US (1) US8637046B2 (es)
EP (1) EP2337582A1 (es)
JP (1) JP5723280B2 (es)
CN (1) CN102238961A (es)
AU (1) AU2009298490A1 (es)
BR (1) BRPI0920800A2 (es)
CA (1) CA2738664C (es)
CL (1) CL2011000742A1 (es)
CO (1) CO6361950A2 (es)
MX (1) MX2011003535A (es)
RU (1) RU2011117241A (es)
WO (1) WO2010039934A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877211B2 (en) * 2011-06-27 2014-11-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Bovine herpes virus vaccine with multiple mutations
CN104640991B (zh) * 2012-07-04 2017-09-19 昆士兰州农渔林业部 重组低毒力1型牛疱疹病毒(BoHV‑1)疫苗载体
CN105343877B (zh) * 2015-11-26 2019-03-01 中国兽医药品监察所 一种5基因缺失伪狂犬病重组病毒活疫苗及其制备方法
WO2017096267A1 (en) * 2015-12-03 2017-06-08 Chowdhury Shafiqul I Bovine herpesvirus type 1 (bohv-1) vector against bovine respiratory disease complex
EP3768307A1 (en) * 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH New ehv with inactivated ul18 and/or ul8
CN113817027A (zh) * 2021-07-13 2021-12-21 中国农业科学院兰州畜牧与兽药研究所 一种牛疱疹病毒Ⅰ型gE蛋白胞外区的原核可溶性表达方法
CN114107230B (zh) * 2021-11-29 2023-08-11 东北农业大学 一种牛疱疹病毒1型ul41缺失毒株及其获取方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593873A (en) 1986-01-27 1997-01-14 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
US6410033B1 (en) 1987-07-27 2002-06-25 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
ME00810B (me) 2002-08-26 2012-03-20 Zoetis Services Llc Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke
US20040185056A1 (en) 2003-01-03 2004-09-23 Board Of Regents, University Of Nebraska-Lincoln Vaccines containing bovine herpesvirus 1 attenuated by mutation in latency-related gene
GB0406389D0 (en) 2004-03-22 2004-04-21 Istituto Superiore Di Sanito Recombinant herpes simplex virus and uses therefor
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
PT1991266E (pt) 2006-01-26 2013-08-28 Zoetis P Llc Novas composições adjuvantes glicolipídicas

Also Published As

Publication number Publication date
CN102238961A (zh) 2011-11-09
BRPI0920800A2 (pt) 2020-08-11
JP2012504417A (ja) 2012-02-23
US8637046B2 (en) 2014-01-28
EP2337582A1 (en) 2011-06-29
WO2010039934A1 (en) 2010-04-08
US20120034262A1 (en) 2012-02-09
RU2011117241A (ru) 2012-11-10
CO6361950A2 (es) 2012-01-20
AU2009298490A1 (en) 2010-04-08
CA2738664A1 (en) 2010-04-08
CA2738664C (en) 2017-10-31
MX2011003535A (es) 2011-09-21
JP5723280B2 (ja) 2015-05-27

Similar Documents

Publication Publication Date Title
CL2011000742A1 (es) Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion.
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EA200701632A1 (ru) Вакцина против вируса ветряной оспы
CL2007002488A1 (es) Sistema de ladrillo para construir paredes y varilla, donde el ladrillo es rectangular y tiene una protuberancia en la cara anterior vertical y una cavidad en la cara posterior vertical, donde encaja una protuberancia de un ladrillo adyacente.
MX2011012347A (es) Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
CY1113738T1 (el) Εμβολια κατα της γριπης χαμηλης περιεκτικοτητας σε προσθετα
BRPI0516323A (pt) construtos de rna
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
EP1948229A4 (en) COMBINED VACCINE COMPRISING AN ATTENUATED VIRUS OF BOVINE VIRAL DIARRHEA
WO2008011609A3 (en) Compositions and methods for vaccinating against hsv-2
BRPI0511802A (pt) processo para criação de meios para uso em separadores de ar/óleo
WO2003079757A3 (en) Hiv therapeutic
WO2007047831A3 (en) Functional influenza virus like particles (vlps)
EP2351843A3 (en) Rabies virus vector systems and compositions and methods thereof
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
CL2013001037A1 (es) Polipeptido gb de citomegalovirus (cmv) que comprende al menos un dominio extracelular de proteina gb; composicion inmunogénica que comprende el polipeptido gb de cmv; metodo para producir respuesta inmune contra cmv.
PE20142330A1 (es) Vacuna de peptido ch3 de ige
WO2014052378A8 (en) Subunit immersion vaccines for fish
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
NO20092254L (no) Pulverformuleringer for valganciclovir
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
CL2009001643S1 (es) Unidad aritmetica y de control para videojuego o similar, de cuerpo paralelepipedico rectangular de sector frontal mas arriba que el sector posterior; el sector posterior inferior tiene en su cara frontal cuatro ranuras circulares, las centrales de menor dimension.
BRPI0514074A (pt) aperfeiçoamentos em composições em bloco para lavatório